EUCTR2012-003531-40-FR进行中（未招募）1 期
Randomised phase II trial of oral vinorelbine and cisplatin followed by maintenance with single agent oral vinorelbine versus gemcitabine and cisplatin followed by maintenance with single agent gemcitabine in first line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological type
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 113
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients must satisfy all the following inclusion criteria before they are allowed to participate in the study:
- •- patient must give written informed consent.
- •- Chemo-naive patients superior or equal to 18 years
- •- Performance status KPS superior or equal to 70% (ECOG/WHO PS 0-1)
- •- Squamous histologically or cytologically (fine needle aspiration is acceptable) proven non-small cell lung cancer.
- •- Stage IIIB (with supra-clavicular nodal metastases), stage IV or relapsing (locally or distant) after a local treatment. Patients not suitable for loco-regional treatment.
- •- Life expectancy more than 12 weeks.
- •- Adequate bone marrow, hepatic and renal functions:
- •· Neutrophils superior or equal to 2.0x109/l, platelets superior or equal to 100x109/l, Haemoglobin superior or equal to 10 g/dl or 6.2 mmol/l.
- •· Total bilirubin inferior or equal to 1.5xULN, Transaminases < 2.5xULN, Alkaline Phosphatases < 5xULN (upper Limit of Normal).
- •· Creatinine < ULN (if limit value, creatinine clearance superior or equal to 60 ml/min).
- •- Prior therapy:
- •· Surgery: patients may have had previous surgery for NSCLC.
- •· Chemotherapy: patients must not have had systemic chemotherapy or immunotherapy.
- •· Radiation therapy: patient may have received prior radiotherapy but not on the site used to assess response. A minimum of 4 weeks interval must have elapsed.
- •- Presence of at least one measurable lesion which has not been previously irradiated (RECIST criteria. Version 1.1). Measurable lesions (measured in at least one dimension, longest diameter to be recorded) as = 20 mm with conventional techniques or as = 10 mm with CT scan. Physical
- •examination and ultrasound will not be considered as objective tumour assessments.
- •- Absence of any psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before randomisation in the trial.
- •- Women of childbearing potential must be using a medically accepted method of contraception (i.e. oral contraceptives, intrauterine devices) to avoid pregnancy during the 2 months preceding the start of study treatment, throughout the study period and for up to 3 months after the last dose of oral vinorelbine or up to 6 months after the last dose of cisplatin in such a manner that the risk of pregnancy is minimised. Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of study treatment.
- •- Fertile men must be using an effective method of birth control if their partners are women of childbearing potential during study period and up to 3 months following the last dose of oral vinorelbine or up to 6 months following the last dose of cisplatin or gemcitabine.
- •- The patient must have access to social insurance according to local regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
排除标准
- •Patients with at least one of the following criteria will not be included:
- •- Known hypersensitivity to the study drug(s) or to drugs with similar chemical structures.
- •- Any important factor likely to modify drug absorption, e.g. surgery of gastro-intestinal tract, significant malabsorption syndrome or disease affecting the gastro-intestinal tract function.
- •- Patients with a local relapse, which is liable to be treated by radiation therapy.
- •- Previous radiotherapy in the only site used to assess response.
- •- Radiotherapy within the previous 4 weeks.
- •- Active central nervous system disorder, brain metastasis or leptomeningeal involvement.
- •- Symptomatic neuropathy (sensory) superior or equal to grade 2 according to the NCI Common Toxicity Criteria (NCI – CTC version 2).
- •- Concomitant/uncontrolled medical disorder (superior cava vein syndrome, cardiac failure or myocardial infarction within the previous 3 months, uncontrolled hypertension or arrhythmia, uncontrolled hypercalcaemia, active infection requiring i.v. antibiotics within 2 weeks before the beginning of treatment).
- •- Weight loss > 10% within the previous 3 months.
- •- Long term oxygen therapy.
- •- Symptomatic ascite or pericardial effusion.
- •- History of another malignancy within the past five years except basal cell carcinoma of the skin or carcinoma in situ of the cervix.
- •- Concomitant treatment with another anticancer or any experimental drug within 30 days prior to the
- •treatment period.
- •- Women if pregnant or lactating or with positive pregnancy test at inclusion; woman of child-bearing potential who did not use or is unwilling or unable to use an acceptable method of contraception to avoid pregnancy during the 2 months preceding the start of study treatment, for the entire study period and for up to 3 months after the last dose of oral vinorelbine or up to 6 months after the last dose of cisplatin.;
- •- Sexually active fertile man not using effective birth control during the study and up to 3 months following the last dose of oral vinorelbine or up to 6 months following the last dose of cisplatin or gemcitabine if his partner is a woman of child-bearing potential.
研究者
相似试验
进行中（未招募）
1 期
Randomised phase II trial to compare two first line chemotherapy regimen : oral vinorelbine and cisplatin followed by maintenance therapy with single agent oral vinorelbine and gemcitabine and cisplatin followed by maintenance therapy with single agent gemcitabine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological type.First line locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) patient with squamous histological type.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003531-40-ITPIERRE FABRE MEDICAMENT110
进行中（未招募）
1 期
Study evaluating oral vinorelbine and cisplatin followed by oral vinorelbine alone versus gemcitabine and cisplatin followed by gemcitabine alone in patients with a specific type of lung cancerFirst line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological typeMedDRA version: 15.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003531-40-ATPierre Fabre Medicament113
进行中（未招募）
1 期
Study evaluating oral vinorelbine and cisplatin followed by oral vinorelbine alone versus gemcitabine and cisplatin followed by gemcitabine alone in patients with a specific type of lung cancerFirst line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological typeMedDRA version: 19.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003531-40-PLPierre Fabre Medicament110
进行中（未招募）
1 期
Study evaluating oral vinorelbine and cisplatin followed by oral vinorelbine alone versus gemcitabine and cisplatin followed by gemcitabine alone in patients with a specific type of lung cancerFirst line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients withsquamous histological typeMedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003531-40-ESPierre Fabre Medicament110
进行中（未招募）
1 期
A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclinesEUCTR2004-000963-81-BEPierre Fabre Medicament230